1. To attract international pharmaceutical/biotechnology companies to perform clinical trials on GI diseases and H. pylori associated diseases in Taiwan, including trials of new drugs, biomarkers, or diagnostic tests.
2. To establish a clinical and basic medical research center for GI diseases as a platform for collaborative research.
3. To help Taiwan pharmaceutical/biotechnology companies develop therapeutic drugs, medical devices and diagnostic modalities in the treatment of GI diseases.
4. To support investigator-initiated studies to solve important health problems.
5. Through collaboration within a cross-hospital trial alliance, we aim to enhance patient enrollment efficiency and improve the generalizability of our study. Coordinating resources within hospitals, including medical databases, and leveraging research expertise, we effectively address critical clinical issues.

International cooperation

1. Our systematic review and meta-analysis showed that the prevalence of antimicrobial resistance in the Asia-Pacific continues increased over time. The Reuters reported this important finding.
2. In 2019, we held a global H. pylori consensus meeting in Taiwan to developed an important global consensus guideline for H. pylori treatment and gastric cancer prevention.

Economic benefits

1. The H. pylori antigen rapid test has been "pre-approved" by the US Food and Drug Administration for its medical device 510(k) pre-market notification permit. This is the first and the only H. pylori antigen rapid test outside the United States that has been approved and marketed by the U.S. FDA.
2. To help publish the introduction of the Covid-19 detection equipment of the QVS-96 in Nat Biotechnol 2020. The Taiwan’s self-made medical equipment obtained the Emergency Use Authorization from the US FDA.

Social influences

1. The net-work analysis of clinical trials including our randomized trial has confirmed that the quadruple therapy and longer treatment days have better eradication efficacies for H. pylori infection.
2. Our randomized trial found that the empirical guided therapy is not inferior to susceptibility guided therapy for treatment of refractory H. pylori infection. This is the first randomized trial in the world to explore this issue.

Important notes of the consortium

• In 2017: Taiwan Clinical Trial Consortium for Gastrointestinal Disease and Helicobacter was established
• In 2017: Our study showed the prevalence of antimicrobial resistance in the Asia-Pacific continues increased over time. (Lancet Gastroenterol Hepatol 2017)

  The Asia-Pacific consortium for Helicobacter pylori disease was established in 2017.

• In 2018: Our net-work analysis of clinical trials including our randomized trial has confirmed that the quadruple therapy and longer treatment days have better eradication efficacies of H. pylori infection. (GUT 2018)
• In 2018: Our randomized trial found that the empirical guided therapy is not inferior to susceptibility guided therapy for treatment of refractory H. pylori infection (Gastroenterology 2018)
• In 2019: The H. pylori antigen rapid test has been "pre-approved" by the US Food and Drug Administration. (Taiwan Panion & BF Biotech Inc.)
• In 2019: Our clinical trial showed that the short-term dysbiosis of gut microbiota after eradication of H. pylori would recover gradually. (Lancet Infect Dis 2019)
• In 2019: The global consensus meeting for global gastric cancer prevention and treatment was held in Taipei in 2019.

  In 2019, the global consensus meeting on H. pylori treatment and gastric cancer prevention was held in Taiwan, and the consensus report was published in the journal “GUT”.

• In 2020: The Covid-19 detection equipment of the QVS-96 was introduced and the Taiwan’s self-made medical equipment obtained the Emergency Use Authorization from the US FDA. (Nat Biotechnol 2020)
• In 2020: To confirm that large-scale community screening and H. pylori eradication can reduce the incidence of gastric cancer. (GUT 2020)

  Assisted in publishing the QVS-96, a new Covid-19 diagnostic device by the Taiwanese company, in the journal “Nat Biotechnol” in 2020.

• In 2021: To be invited to write an article discussing the relationship between H. pylori and gut microbiota. (GUT microbes 2021)
• In 2021: The PI of our consortium, Professor Jyh-Ming Liu, was invited to be the leader of “Gastric cancer prevention” working group in 2021 Maastricht consensus meeting.
• In 2021: The PI was invited to write a review article in the top GI journal. (Clin Gastroenterol Hepatol 2021)

  In 2021, the principal investigator (PI) was invited to write a review article in the journal “Clin Gastroenterol Hepatol”.

• In 2022: Professor Jyh-Ming Liou was invited to be the co-convener and co-author of “Maastricht consensus report VI”. The report of the consensus meeting was published in GUT 2022.
• In 2022: Participated in the formulation of "The Taiwan Guideline for Screening and Eradication of Helicobacter pylori Infection for Gastric Cancer Prevention".

  In 2022, the principal investigator (PI) was invited to be the co-convener and co-author of “Maastricht consensus report VI”. The report of the consensus meeting was published in the journal “GUT”.

• In 2023: Regarding "The effects of H. pylori eradication on gut microbiota and antibiotic resistome", our report of clinical trial was published in an important international journal (The Lancet Gastroenterology & Hepatology)
• In 2023: Two multicenter clinical trials discovered that eradication efficacy of the molecular testing-guided therapy are similar to that of traditional antibiotic susceptibility testing-guided therapy. Our research paper on this topic was published in the important international journal, "The Lancet Gastroenterology & Hepatology", in July 2023.

  Regarding "The effects of H. pylori eradication on gut microbiota and antibiotic resistome", our clinical trial was published in the journal “The Lancet Gastroenterology & Hepatology)” and the paper was selected for the cover of the respective issue in March 2023.

Our two multicenter clinical trials found that the eradication efficacy of the molecular testing-guided therapy are similar to that of traditional antibiotic susceptibility testing-guided therapy. The results were published in the journal “The Lancet Gastroenterology & Hepatology)” and the paper was selected for the cover of the respective issue in July 2023.